Deferasirox (ExJade): A Fluorescent Pro-Chelator Active Against Antibiotic Resistant Bacteria

30 March 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Deferasirox, ExJade, an FDA-approved treatment for iron overload disorders has been shown to inhibit the growth of both gram-positive and -negative bacteria through iron (Fe(III)) chelation. Modification of the ExJade framework led to the identification of a new fluorescent platform ExPh and ExBT. Functionalization of the phenol moieties on ExBT with phosphate units afforded a ratiometric fluorescent pro-chelator (ExPhos), which was effective in the inhibition of two clinically relevant antibiotic-resistant bacteria, (MRSA (ATCC 43300) and VRE (ATCC 51299)), and allowed the fluorescent imaging of MRSA. Remarkably, this pro-chelation strategy proved selective towards bacteria with no cytotoxicity observed for ExPhos treated A549 cells (72 h incubation). This work represents a new pro-chelator antibiotic strategy that can be modified with a chosen reactive chemical trigger to provide a diagnostic signal in conjunction with a therapeutic response with a potential of minimal off-target toxicities.

Keywords

Antibiotic resistance bacteria
Fluorescence imaging
Aggregation induced emission

Supplementary materials

Title
Description
Actions
Title
ExJade ESI Final
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.